|
Registration benefits include:
|
|
Access to CME/CE programs and certification
|
|
|
Free subscription to Biologic Bulletin newsletter
|
|
|
Reminders of new CME/CE activities
|
 REGISTER NOW
|
|
|
|
|
|
 |
| CME/CE Programs : CE Programs |
Please select from the following activities:
Featured CE Activity
|
|
CME-Certified Biologic Bulletin Edited by Bruce Strober, MD, PhD and Melodie Young, MSN, RN, A/GNP-C
The systemic inflammatory nature of psoriasis and its association with cardiovascular comorbidities are important considerations for the management of patients with psoriasis. Moreover, the recognition that younger patients with more severe disease are at increased risk for poor cardiovascular outcomes warrants early detection of patients who are most at risk for cardiovascular disease. This Biologic Bulletin examines the risk for cardiovascular disease in patients with psoriasis, the mechanisms that contribute to cardiovascular comorbidites, and the effect that psoriasis treatment has on cardiovascular outcomes.
|
|
Additional CE Activity
|
|
Clinically Challenging Cases: Expert Insights
Presented by Jeffrey J. Crowley, MD and Melodie Young, MSN, RN, A/GNP-C
A 62-year-old male patient presents to your virtual office with severe psoriasis. Among the issues that you need to consider are this patient’s previous history of renal cell carcinoma, active hepatitis C, and alcoholism. You—in consultation with Jeffrey Crowley, MD and Melodie Young, MSN, RN, A/GNP-C—are managing his care. "Consult" with Dr. Crowley and your colleagues as you consider treatment options for this complex case. This activity follows the progression of the case, solicits your clinical input on key aspects of treatment, and presents recommendations provided by other clinicians that have "consulted" on this case.
CME-Certified Biologic Bulletin Edited by Jeffrey J. Crowley, MD and Neil J. Korman, MD, PhD
This Biologic Bulletin examines how clinicians can utilize biologics to improve outcomes for their patients with psoriasis. The newsletter highlights some common ways in which patient characteristics can be considered in tailoring treatment decisions. It also examines new data on the long-term safety and efficacy of biologics. This Biologic Bulletin uses a case-based approach to illustrate the clinical decisions involved in developing a treatment strategy for patients with moderate to severe psoriasis.
This interactive CME/CNE-certified activity features an update on the pathophysioloy of psoriasis and evolving clinical data on novel agents in clinical development.
Our evolving understanding of the role of new pathways and newly discovered cell populations involved in the pathophysiology of psoriasis offers the potential for novel drug targets and therapeutic agents. A more thorough appreciation of the pathophysiology of psoriasis and the role of certain cell populations and cytokines will help clinicians better understand both the mechanisms of disease and the mechanisms of therapeutic intervention with biologic agents. As novel agents advance in clinical development, clinicians need updates on their mechanisms of action, safety and efficacy profiles, and where they fit into clinical practice.
|
| VIEW ACTIVITY
|
|
|
|
|
|
